由於資金限制、臨床高成本和流失率高、監管不確定性、對治療安全性和有效性難以動搖的疑慮以及普遍對指導該領域研究的基礎生物學缺乏了解，讓突破性癌症免疫療法的商業化越來越具有挑戰性。但在我們制定 2025 年會議議程時，我們驚訝地發現，儘管面臨這些挑戰，人們仍然強烈希望尋找治療實體腫瘤的有效方法。 第 13 屆 Immuno-Oncology Summit 將展示基於對生物學深刻理解的臨床前和臨床試驗成功案例。內容涵蓋了實體瘤領域的創新，包括雙特異性/多特異性抗體、抗體-藥物偶聯物 （ADC）、同種異體和體內 CAR-T、TIL、TCR、Treg、多細胞治療合作、腫瘤微環境、先天免疫、γ-δ T 細胞、NK 細胞、類器官建模、數據科學和機器學習。該計劃還將自體免疫作為一個重要且互補的重點領域進行探索。
2025年的全體會議主題演講者
Off-the-Shelf Allogeneic CAR T Therapy in the Treatment of Severe Autoimmune Diseases
Biao Zheng, PhD
CEO, BRL Medicine
PANEL DISCUSSION: Advancing Immunotherapy: Strategies for Preventing Attrition
Moderator:
Rakesh Dixit, PhD, DABT
President & Founder, Bionavigen Oncology, LLC and Regio Biosciences
Carter Caldwell, MBA
Co-Investment Program Director, University of Pennsylvania
Karen Chagin, MD
Senior Vice President, Early Stage Development, Adaptimmune
Margery Ma, PhD
Principal Consultant, NonClinical Regulatory Affairs, Eliquent Life Sciences
David Sommerhalder, MD
Clinical Investigator, Oncology, NEXT Oncology
PANEL DISCUSSION: Accelerating IO through Target Discovery
Moderator:
Tatiana Novobrantseva, PhD
CSO, NextPoint Therapeutics
Vitalay Fomin, PhD
Co-Founder, Numenos AI
Shameer Khader, PhD
Executive Director, Global Head of Data Science, Data Engineering and Computational Biology, Sanofi
Kristen Meerbrey, PhD
Director of Target Discovery, Therapeutic Innovation Center, Baylor College of Medicine
感謝我們 2025 年的贊助商
Corporate Support Sponsors:
